These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33205259)

  • 1. Glycoproteomics Technologies in Glycobiotechnology.
    Alagesan K; Hoffmann M; Rapp E; Kolarich D
    Adv Biochem Eng Biotechnol; 2021; 175():413-434. PubMed ID: 33205259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. State-of-the-Art Glycomics Technologies in Glycobiotechnology.
    Pralow A; Cajic S; Alagesan K; Kolarich D; Rapp E
    Adv Biochem Eng Biotechnol; 2021; 175():379-411. PubMed ID: 33112988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-glycan Analysis in Molecular Medicine: Innovator and Biosimilar Protein Therapeutics.
    Borza B; Hajba L; Guttman A
    Curr Mol Med; 2020; 20(10):828-839. PubMed ID: 33272172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical detection and characterization of biopharmaceutical glycosylation by MS.
    Oh MJ; Hua S; Kim U; Kim HJ; Lee J; Kim JH; An HJ
    Bioanalysis; 2016 Apr; 8(7):711-27. PubMed ID: 26964748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept.
    Montacir O; Montacir H; Springer A; Hinderlich S; Mahboudi F; Saadati A; Parr MK
    Protein J; 2018 Apr; 37(2):164-179. PubMed ID: 29411222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrepancies between High-Resolution Native and Glycopeptide-Centric Mass Spectrometric Approaches: A Case Study into the Glycosylation of Erythropoietin Variants.
    Čaval T; Buettner A; Haberger M; Reusch D; Heck AJR
    J Am Soc Mass Spectrom; 2021 Aug; 32(8):2099-2104. PubMed ID: 33856811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparability study of Rituximab originator and follow-on biopharmaceutical.
    Montacir O; Montacir H; Eravci M; Springer A; Hinderlich S; Saadati A; Parr MK
    J Pharm Biomed Anal; 2017 Jun; 140():239-251. PubMed ID: 28371718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry.
    Zhu L; Guo Q; Guo H; Liu T; Zheng Y; Gu P; Chen X; Wang H; Hou S; Guo Y
    MAbs; 2014; 6(6):1474-85. PubMed ID: 25484062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equivalence assessment of biotherapeutics with N- and O-glycosylation sites by sequential intact glycoform mass spectrometry (IGMS).
    Oh MJ; Kim U; Kim S; Cho DS; Seo JA; Seo N; An HJ
    J Pharm Biomed Anal; 2023 Sep; 234():115558. PubMed ID: 37393692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycosimilarity assessment of biotherapeutics 1: Quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept.
    Borza B; Szigeti M; Szekrenyes A; Hajba L; Guttman A
    J Pharm Biomed Anal; 2018 May; 153():182-185. PubMed ID: 29499461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycan characterization of biopharmaceuticals: Updates and perspectives.
    Planinc A; Bones J; Dejaegher B; Van Antwerpen P; Delporte C
    Anal Chim Acta; 2016 May; 921():13-27. PubMed ID: 27126786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications.
    Duivelshof BL; Jiskoot W; Beck A; Veuthey JL; Guillarme D; D'Atri V
    Anal Chim Acta; 2019 Dec; 1089():1-18. PubMed ID: 31627805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative Metrics for Reporting and Comparing the Glycan Structural Profile in Biotherapeutics.
    Mastrangeli R; Satwekar A; Bierau H
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the glycosylation aspects of biosimilarity.
    Hajba L; Szekrényes Á; Borza B; Guttman A
    Drug Discov Today; 2018 Mar; 23(3):616-625. PubMed ID: 29337201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study.
    Joshi S; Rathore AS
    BioDrugs; 2020 Apr; 34(2):209-223. PubMed ID: 31975160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.
    D'Atri V; Fekete S; Beck A; Lauber M; Guillarme D
    Anal Chem; 2017 Feb; 89(3):2086-2092. PubMed ID: 28208257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms.
    Nupur N; Joshi S; Gulliarme D; Rathore AS
    Front Bioeng Biotechnol; 2022; 10():832059. PubMed ID: 35223794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advancements, challenges, and practical considerations in the mass spectrometry-based analytics of protein biotherapeutics: A viewpoint from the biosimilar industry.
    Háda V; Bagdi A; Bihari Z; Timári SB; Fizil Á; Szántay C
    J Pharm Biomed Anal; 2018 Nov; 161():214-238. PubMed ID: 30205300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical comparability assessment on glycosylation of ziv-aflibercept and the biosimilar candidate.
    Shen Z; Wang Y; Xu H; Zhang Q; Sha C; Sun B; Li Q
    Int J Biol Macromol; 2021 Jun; 180():494-509. PubMed ID: 33684428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.